Skip to main content

Table 2 Clinical features and NAT polymorphisms in 25 AS patients who experienced SSZ-induced ADRs

From: Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine

ADR types*

Cases

SSZ Dose (g/day)

ADR

Termination of Drug therapy

NAT2

NAT1

Genotypes

Acetylator

genotypes

Genotypes

Acetylator

genotypes

Dose-related

Case 1

3.0

Nausea

No

NAT2*4/NAT2*7

Fast

NAT1*10/NAT1*10

Fast

 

Case 2

3.0

Nausea, anorexia

No

NAT2*4/NAT2*5

Fast

NAT1*3/NAT1*10

Fast

 

Case 3

1.5

Abdominal pain

Yes

NAT2*4/NAT2*6

Fast

NAT1*4/NAT1*10

Fast

 

Case 4

3.0

Diarrhea

Yes

NAT2*7/NAT2*7

Slow

NAT1*4/NAT1*4

Slow

 

Case 5

3.0

Diarrhea

No

NAT2*5/NAT2*7

Slow

NAT1*4/NAT1*4

Slow

 

Case 6

3.0

Epigastric discomfort

No

NAT2*4/NAT2*4

Fast

NAT1*4/NAT1*10

Fast

 

Case 7

1.5

Epigastric discomfort

Yes

NAT2*4/NAT2*7

Fast

NAT1*4/NAT1*10

Fast

 

Case 8

1.5

Increase in transaminases

Yes

NAT2*6/NAT2*7

Slow

NAT1*4/NAT1*4

Slow

 

Case 9#

2.25

Increase in transaminases

Yes

NAT2*6/NAT2*7

Slow

NAT1*4/NAT1*3

Slow

 

Case 10

2.25

Dizziness

No

NAT2*6/NAT2*7

Slow

NAT1*3/NAT1*3

Slow

 

Case 11

1.5

Dizziness

Yes

NAT2*6/NAT2*6

Slow

NAT1*4/NAT1*4

Slow

 

Case 12

1.5

Dizziness

Yes

NAT2*5/NAT2*6

Slow

NAT1*4/NAT1*4

Slow

 

Case 13

1.5

Dizziness

Yes

NAT2*4/NAT2*7

Fast

NAT1*10/NAT1*10

Fast

 

Case 14

1.5

Dizziness

Yes

NAT2*6/NAT2*6

Slow

NAT1*4/NAT1*4

Slow

 

Case 15

3.0

Dizziness

No

NAT2*4/NAT2*4

Fast

NAT1*4/NAT1*4

Slow

 

Case 16

1.5

Chest congestion

Yes

NAT2*5/NAT2*6

Slow

NAT1*4/NAT1*3

Slow

Non-dose-related

Case 17

2.25

Leukopenia

Yes

NAT2*4/NAT2*6

Fast

NAT1*4/NAT1*4

Slow

 

Case 18

1.5

Rash

Yes

NAT2*6/NAT2*6

Slow

NAT1*4/NAT1*4

Slow

 

Case 19

1.5

Rash

Yes

NAT2*4/NAT2*6

Fast

NAT1*3/NAT1*10

Fast

 

Case 20

1.5

Rash

Yes

NAT2*4/NAT2*6

Fast

NAT1*4/NAT1*11

Slow

 

Case 21

3.0

Rash

Yes

NAT2*4/NAT2*4

Fast

NAT1*4/NAT1*10

Fast

 

Case 22

3.0

Rash

Yes

NAT2*4/NAT2*4

Fast

NAT1*3/NAT1*10

Fast

 

Case 23

2.25

Oral ulcer

Yes

NAT2*4/NAT2*4

Fast

NAT1*10/NAT1*10

Fast

 

Case 24

2.25

Oral ulcer

Yes

NAT2*4/NAT2*4

Fast

NAT1*4/NAT1*10

Fast

Time-related

Case 25#

2.25

Cacospermia

Yes

NAT2*4/NAT2*6

Fast

NAT1*3/NAT1*3

Slow

  1. *ADRs were classified into six types: dose-related, non-dose-related, dose-related and time-related, time-related, withdrawal (End of use), and failure of therapy; #Case 9 was observed to have elevated serum liver enzyme levels at day 138 and case 25 had cacospermia at day 450 after the start of SSZ treatment; ADRs = Adverse Drug Reactions; NAT1 = Arylamine N-acetyltransferases 1; NAT2 = Arylamine N-acetyltransferases 2; SSZ = Sulfasalazine.